Drugs / imipenem/cilastatin
last change Feb 2003 re-read 2 minutes ago

imipenem/cilastatin

Developed for
bacterial pneumonia
Investigated by
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. · PriCara, Unit of Ortho-McNeil, Inc.

Trials 1 · a red edge is where a trial was stopped

199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 3 NCT00236834 Dec 1997 → Jun 2001 bacterial pneumonia Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Completed No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as imipenem/cilastatin “The goal of this study was to compare the efficacy and safety of levofloxacin 750 mg and imipenem/cilastatin followed by ciprofloxacin in adult patients with nosocomial pneumonia.” PMID 12749509 Feb 2003
Route Intravenous “imipenem/cilastatin 500 mg to 1 g i.v. every 6 to 8 hours” PMID 12749509 Feb 2003